HIV prevention drug lenacapavir safe and effective in trial

The East African July 6, 2024, 02:00 PM UTC

Summary: A Phase 3 clinical trial found lenacapavir, a novel injectable HIV prevention drug, to be safe and 100% effective when administered twice a year to cisgender women. This breakthrough could revolutionize HIV prevention strategies, potentially reducing new infections significantly. Lenacapavir inhibits HIV replication by targeting the virus's capsid protein. The drug's bi-annual dosing schedule simplifies prevention regimens. Regulatory approvals and pricing remain key challenges for widespread implementation.

Full article

Article metrics
Significance5.2
Scale7.0
Magnitude8.0
Novelty9.0
Actionability6.0
Immediacy8.0
Positivity9.0
Probability7.0
Credibility6.5

Timeline:

  1. [4.4]
    Biannual lenacapavir injection 100% effective in preventing HIV (News Karnataka)
    23h
    Source
  2. [5.1]
    UNAIDS urges global access to new HIV drug Lenacapavir (Marketscreener.com)
    4d

  3. [6.3]
    New HIV prevention drug lenacapavir shows 100% efficacy (ScienceAlert)
    5d

  4. [4.6]
    Biannual Lenacapavir injection 100% effective against HIV (WION)
    7d
    Source
  5. [5.8]
    Lenacapavir injection offers 100% HIV protection to young women (Hindustan Times)
    8d

  6. [6.1]
    HIV prevention injection successful in South Africa trial (AllAfrica - Top Africa News)
    14d